Yes. Colchicine is an anti-inflammatory medicine. It gathers inside white blood cells and blocks a switch that makes two inflammation signals, IL-1 beta and IL-18. In large trials it lowered CRP, a blood marker of inflammation. In people who already have heart disease, it cut heart attacks and strokes by a modest amount.
An old drug with a narrow job
Colchicine is old. Its first use as a medicine goes back to ancient Egypt. For most of its life it had one main job: treating and preventing gout attacks. It has since become a standard treatment for pericarditis, which is inflammation of the sac around the heart.
Gout doctors still lean on it. The 2020 American College of Rheumatology guideline strongly recommends colchicine, anti-inflammatory painkillers or steroids for gout flares.
So the drug was never in doubt as a way to calm a flare. The newer question was bigger. Could it calm the slow, hidden kind of inflammation that builds up in arteries?
How is colchicine anti-inflammatory?
Most anti-inflammatory drugs work all over the body. Colchicine is pickier. It concentrates inside white blood cells, especially neutrophils, the first responders of the immune system.
At 3 months, CRP was 1.28 mg per liter lower on colchicine than on placebo.From a 2025 randomized trial in N Engl J Med
Once inside, it does two things. It stops the cell from building microtubules, the tiny tubes a cell uses to move and react. And it blocks the NLRP3 inflammasome, a cluster of proteins that switches on inflammation. With that switch held down, cells make less IL-1 beta and IL-18. Those two signals help fatty plaque form, grow and break open inside arteries.
A 2026 review adds more. Colchicine also limits oxidative stress, slows the formation of cholesterol crystals, and acts on many cell types in the blood vessel wall. Together, the authors write, those actions reduce inflammation in blood vessels and help keep plaque stable.
That last point is the bridge from the gout clinic to the heart clinic.
Can a gout drug protect the heart?
Researchers had long seen inflammation as part of how arteries clog and fail. Colchicine gave them a cheap, familiar way to test the idea in people.
The first big test came in 2019. The COLCOT trial gave 4,745 people either 0.5 mg of colchicine a day or a placebo, starting within 30 days of a heart attack. Over a median of 22.6 months, 5.5% of the colchicine group had a major heart or stroke event, compared with 7.1% on placebo.
A year later, LoDoCo2 tested the same dose in 5,522 people with long-term coronary disease. Over a median of 28.6 months, 187 people on colchicine (6.8%) had a main event, compared with 264 on placebo (9.6%).
Two large trials pointed the same way. For a moment, it looked settled.
Then a bigger trial found nothing
In 2025, the CLEAR trial enrolled 7,062 people at 104 centers in 14 countries, all starting soon after a heart attack. After a median of 3 years, 322 of 3,528 people on colchicine (9.1%) had a main event. On placebo it was 327 of 3,534 (9.3%). No difference.
Here is the strange part. The drug still did its anti-inflammatory job. At 3 months, CRP was 1.28 mg per liter lower in the colchicine group than in the placebo group. Inflammation went down. Heart events did not.
Stroke trials have been mixed too. In CONVINCE, 3,154 people who had a stroke or mini-stroke got colchicine plus usual care or usual care alone. Events happened in 153 of 1,569 people on colchicine and 185 of 1,575 without it, a gap too small to rule out chance. Yet people on colchicine had lower CRP at 28 days and at 1, 2 and 3 years. The 2026 review notes that several recent trials in stroke and brain blood vessel disease have come back neutral.
What all the trials say together
When results clash, pooling them helps. A 2025 Cochrane review combined 12 trials with 22,983 people who had heart disease or a past stroke, using 0.5 mg once or twice a day. It found high-certainty evidence that colchicine lowers heart attacks (about 9 fewer per 1,000 people) and strokes (about 8 fewer per 1,000). It did not raise serious side effects. But it probably made little to no difference in deaths from any cause.
A second 2025 analysis of 9 trials in people with coronary disease or stroke found that colchicine cut the combined risk of heart death, heart attack or stroke by 12%.
Keep in mind who was tested. Most people in these trials were men (79.4%), with average ages from 57 to 74.
The side effects, and the statin catch
The most common problem is the gut. In the Cochrane review, stomach and bowel side effects were more common on colchicine, though usually mild and short-lived. In CLEAR, diarrhea hit 10.2% of people on colchicine and 6.6% on placebo. Pooled trials also found more hospital stays for gut problems, but no rise in pneumonia, new cancers or deaths from other causes.
The bigger safety issue is a drug pairing. Colchicine and statins, the common cholesterol drugs, are cleared by the same pathway in the body. A 2022 review found 38 people who had harm on the pair. In 25 it was muscle damage and in 10 it was a severe muscle breakdown called rhabdomyolysis. Risk was higher with kidney disease or cirrhosis, with colchicine doses of 1.2 mg a day or more, and with other drugs that use the same pathway.
What this means for you
Tick what you'll try this week. Your picks stay on this device.
you take a statin or other daily medicines; you have kidney disease, liver disease or cirrhosis; you get muscle pain, weakness or dark urine while taking colchicine; you have diarrhea that does not settle; or you are pregnant, breastfeeding, or thinking about colchicine for a child.
One tap. Results appear once 50 readers have voted, and the count is always real.
The bottom line
An ancient remedy, a switch inside white blood cells, CRP falling in trial after trial. Then heart results that held up in some trials and vanished in others. Put together, they say one clear thing. Colchicine is anti-inflammatory, and the heart trials showed that calming inflammation can protect some hearts, a little. It is a prescription medicine for people with heart disease, chosen with a doctor. It is not a shortcut for anyone else.
Common questions
Does colchicine reduce inflammation in the body?
Yes. In the CLEAR trial, CRP was 1.28 mg per liter lower after 3 months on colchicine than on placebo. In the CONVINCE stroke trial, people on colchicine had lower CRP at 28 days and at 1, 2 and 3 years. It works by blocking the NLRP3 inflammasome inside white blood cells, which cuts the signals IL-1 beta and IL-18.
How does colchicine help the heart?
Inflammation helps fatty plaque form, grow and break open in arteries. Colchicine damps that inflammation in blood vessels and helps keep plaque stable. In 12 trials of people with heart disease, it led to about 9 fewer heart attacks and 8 fewer strokes per 1,000 people. It did not change deaths from any cause.
Is colchicine an anti-inflammatory drug like an NSAID?
It is anti-inflammatory, but it works in a different way. Gout guidelines list colchicine as its own option, next to nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids. Instead of acting all over the body, colchicine collects in white blood cells, blocks their microtubules, and holds down the NLRP3 inflammasome.
Should healthy people take colchicine to lower inflammation?
The evidence does not support it. A 2025 Cochrane review of 15 trials in people without heart disease found the results very uncertain for every outcome, and many of those trials were really about liver disease. Colchicine also raised the chance of diarrhea in those trials.
Ask the Research Desk
Heard something about inflammation you want checked? The best questions become articles, credited by first name only if you say yes.
How this article was made
Researched and written from 11 peer-reviewed papers. Our automated check matched every claim against the exact words of its source, confirmed every paper exists in PubMed, and found none retracted. Checked November 1, 2026. Not individually reviewed by a doctor. Photos are illustrative; the people in them are not patients or readers.
Grades run Strong, Moderate, Emerging, Early and Not supported, and the grade decides the words we may use. How we grade evidence · Medical disclaimer
Sources
- Meta-analysisColchicine for the secondary prevention of cardiovascular events.Ebrahimi F, Ebrahimi R, Beer M et al. Cochrane Database Syst Rev, 2025.PubMedFull paper
- Randomized trialEfficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.Tardif JC, Kouz S, Waters DD et al. N Engl J Med, 2019.PubMedFull paper
- Randomized trialColchicine in Patients with Chronic Coronary Disease.Nidorf SM, Fiolet ATL, Mosterd A et al. N Engl J Med, 2020.PubMedFull paper
- Randomized trialColchicine in Acute Myocardial Infarction.Jolly SS, d'Entremont MA, Lee SF et al. N Engl J Med, 2025.PubMedFull paper
- Meta-analysisColchicine for secondary prevention of vascular events: a meta-analysis of trials.d'Entremont MA, Poorthuis MHF, Fiolet ATL et al. Eur Heart J, 2025.PubMedFull paper
- Randomized trialLong-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.Kelly P, Lemmens R, Weimar C et al. Lancet, 2024.PubMedFull paper
- ReviewColchicine for acute and chronic coronary syndromes.Imazio M, Andreis A, Brucato A et al. Heart, 2020.PubMedFull paper
- ReviewMechanisms and therapeutic potential of colchicine in atherosclerotic cardiovascular disease.Xia X, Yang F, Liao Y et al. Nat Cardiovasc Res, 2026.PubMedFull paper
- Guideline2020 American College of Rheumatology Guideline for the Management of Gout.FitzGerald JD, Dalbeth N, Mikuls T et al. Arthritis Care Res (Hoboken), 2020.PubMedFull paper
- Meta-analysisColchicine for the primary prevention of cardiovascular events.Martí-Carvajal AJ, Gemmato-Valecillos MA, Monge Martín D et al. Cochrane Database Syst Rev, 2025.PubMedFull paper
- Systematic reviewA systematic review of the drug-drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies.Schwier NC, Cornelio CK, Boylan PM Pharmacotherapy, 2022.PubMedFull paper
